Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. [electronic resource]
Producer: 20130329Description: 616-22 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Colitis -- chemically induced
- Diarrhea -- chemically induced
- Drug Administration Schedule
- Drug Eruptions -- etiology
- Fatigue -- chemically induced
- Female
- Humans
- Ipilimumab
- Kaplan-Meier Estimate
- Male
- Melanoma -- drug therapy
- Middle Aged
- Nausea -- chemically induced
- Pruritus -- chemically induced
- Salvage Therapy -- methods
- Skin Neoplasms -- drug therapy
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.